Abstract Search

ea0099oc7.2 | Oral Communications 7: Endocrine-related Cancer | ECE2024

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

Ferone Diego , Halperin Daniel , Myrehaug Sten , Herrmann Ken , Pavel Marianne , Kunz Pamela , Chasen Beth , Capdevila Jaume , Tafuto Salvatore , Oh Do-Youn , Yoo Changhoon , Falk Stephen , Halfdanarson Thorvardur R , Folitar Ilya , Zhang Yufen , Santoro Paola , Aimone Paola , de Herder Wouter W , Singh Simron

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...

0 shares

Endocrine Abstracts

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

BiosciAbstracts